145 related articles for article (PubMed ID: 7790116)
1. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model.
Kroesen BJ; Helfrich W; Bakker A; Wubbena AS; Bakker H; Kal HB; The TH; de Leij L
Int J Cancer; 1995 Jun; 61(6):812-8. PubMed ID: 7790116
[TBL] [Abstract][Full Text] [Related]
2. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.
Kroesen BJ; Bakker A; van Lier RA; The HT; de Leij L
Cancer Res; 1995 Oct; 55(19):4409-15. PubMed ID: 7545540
[TBL] [Abstract][Full Text] [Related]
4. An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy.
McLaughlin PM; Kroesen BJ; Dokter WH; van der Molen H; de Groot M; Brinker MG; Kok K; Ruiters MH; Buys CH; de Leij LF
Cancer Immunol Immunother; 1999 Sep; 48(6):303-11. PubMed ID: 10473805
[TBL] [Abstract][Full Text] [Related]
5. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
[TBL] [Abstract][Full Text] [Related]
6. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
7. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
8. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
9. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
[TBL] [Abstract][Full Text] [Related]
10. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
11. The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity.
Kroesen BJ; Wellenberg GJ; Bakker A; Helfrich W; The TH; de Leij L
Br J Cancer; 1996 Mar; 73(6):721-7. PubMed ID: 8611371
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
[TBL] [Abstract][Full Text] [Related]
13. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.
Janssen RA; Kroesen BJ; Buter J; Mesander G; Sleijfer DT; The TH; Mulder NH; de Leij L
Br J Cancer; 1995 Sep; 72(3):795-9. PubMed ID: 7669598
[TBL] [Abstract][Full Text] [Related]
15. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.
Kroesen BJ; ter Haar A; Spakman H; Willemse P; Sleijfer DT; de Vries EG; Mulder NH; Berendsen HH; Limburg PC; The TH
Cancer Immunol Immunother; 1993 Nov; 37(6):400-7. PubMed ID: 7902211
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
17. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy.
McLaughlin PM; Harmsen MC; Dokter WH; Kroesen BJ; van der Molen H; Brinker MG; Hollema H; Ruiters MH; Buys CH; de Leij LF
Cancer Res; 2001 May; 61(10):4105-11. PubMed ID: 11358833
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.
Zeidler R; Reisbach G; Wollenberg B; Lang S; Chaubal S; Schmitt B; Lindhofer H
J Immunol; 1999 Aug; 163(3):1246-52. PubMed ID: 10415020
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
[TBL] [Abstract][Full Text] [Related]
20. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
